The TIGIT class claimed its latest casualty as iTeos Therapeutics’ belrestotug failed to show sufficient benefit in trials of patients with non-small cell lung cancer (NSCLC) and head and neck cancer, leading them to call off the drug’s development program. It is a major letdown even for a class that has seen several failures as belrestotug had been considered a leader among TIGIT inhibitors. The trial results led iTeos and partner GSK plc to terminate their collaboration and forced iTeos to pursue strategic alternatives.
Key Takeaways
- iTeos said it is pursuing strategic alternatives after Phase II studies of belrestotug failed to meet efficacy expectations.
The Belgian-American biotech disclosed on 13 May the results of the Phase II GALAXIES Lung-02 platform study testing the combination...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
